Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(17):1257; doi:10.1093/jnci/95.17.1257
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wang, L.
Right arrow Articles by Arnold, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

Press Release

Bone Loss Prevention Drug Showing Promise in Advanced Prostate Cancer

Linda Wang, Assistant News Editor, Katherine Arnold, News Editor

jncimedia@oupjournals.org

The first 10% of the full text of this article appears below.

Oral sodium clodronate may slow the development of symptomatic bone metastases and reduce the risk of death in men with advanced prostate cancer, according to a randomized controlled trial in the September 3 issue of the Journal of the National Cancer Institute.

Prostate cancer spreads most commonly to the bone, and bone metastases affect at least 85% of men with advanced . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?